CI994 (Tacedinaline) --- HDAC Inhibitor

Bioss

CI994 (Tacedinaline) --- HDAC Inhibitor [112522-64-2]

16

Research Use Only

98.0

CI994 is a potent, selective and orally active histone deacetylase (HDAC) inhibitor. It inhibits HDAC1 (IC50 ~0.57 microM), HDAC2 (IC50 ~0.90 microM) and HDAC3 (IC50 ~1.2 microM). It does not inhibit HDAC6 and HDAC8 (IC50 >100 microM). CI994 mediates G1 cell cycle arrest, inhibits proliferation, and induces apoptosis in tumor cell lines. It has also demonstrated antitumor activity in several tumor models, including the chemo-resistant mouse pancreatic ductal carcinoma as well as the human prostate tumor model LNCaP. Currently CI994 is in phase III clinical trials for lung cancer. In recent publication CI994 could also epigenetically prime the hippocampal transcriptome for reinstated neuroplasticity and lead to increased neuroplasticity during memory extinction. This suggests applying HDACis during memory reconsolidation might constitute a treatment option for remote traumata.

-20°C

51202000